{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T13:54:54Z","timestamp":1768485294060,"version":"3.49.0"},"reference-count":25,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Growth Hormone & IGF Research"],"published-print":{"date-parts":[[2020,4]]},"DOI":"10.1016\/j.ghir.2020.01.001","type":"journal-article","created":{"date-parts":[[2020,1,13]],"date-time":"2020-01-13T02:19:52Z","timestamp":1578881992000},"page":"22-26","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Therapy with recombinant human IGF-1 for children with primary insulin-like growth factor-I deficiency"],"prefix":"10.1016","volume":"51","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2398-9520","authenticated-orcid":false,"given":"Philippe","family":"Backeljauw","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ghir.2020.01.001_bb0005","series-title":"The Court of the Gonzaga in the Age of Mantegna: 1450\u20131550. Bulzoni","first-page":"179","article-title":"Mantegna\u2019s camera picta as wall decoration","author":"Martindale","year":"1997"},{"issue":"2","key":"10.1016\/j.ghir.2020.01.001_bb0010","first-page":"152","article-title":"Genetic pituitary dwarfism with high serum concentration of growth hormone - a new inborn error of metabolism?","volume":"2","author":"Laron","year":"1966","journal-title":"Isr. J. Med. Sci."},{"issue":"24","key":"10.1016\/j.ghir.2020.01.001_bb0015","doi-asserted-by":"crossref","first-page":"13215","DOI":"10.1073\/pnas.94.24.13215","article-title":"Kopchick JJ. A mammalian model for Laron syndrome produced by targeted disruption of the mouse growth hormone receptor\/binding protein gene (the Laron mouse)","volume":"94","author":"Zhou","year":"1997","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"20","key":"10.1016\/j.ghir.2020.01.001_bb0020","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1056\/NEJM199011153232002","article-title":"The little women of Loja--growth hormone-receptor deficiency in an inbred population of southern Ecuador","volume":"323","author":"Rosenbloom","year":"1990","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.ghir.2020.01.001_bb0025","first-page":"444","article-title":"Clinical, biochemical, and molecular investigations of a genetic isolate of growth hormone insensitivity (Laron\u2019s syndrome)","volume":"82","author":"Baumbach","year":"1997","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"21","key":"10.1016\/j.ghir.2020.01.001_bb0030","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1056\/NEJM199105233242107","article-title":"Effects of the infusion of insulin-like growth factor I in a child with growth hormone insensitivity syndrome (Laron dwarfism)","volume":"324","author":"Walker","year":"1991","journal-title":"N Engl J Med."},{"issue":"1","key":"10.1016\/j.ghir.2020.01.001_bb0035","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1159\/000351958","article-title":"Adult and near-adult height in patients with severe insulin-like growth factor-I deficiency after long-term therapy with recombinant human insulin-like growth factor-I","volume":"80","author":"Backeljauw","year":"2013","journal-title":"Horm Res Paediatr."},{"issue":"3","key":"10.1016\/j.ghir.2020.01.001_bb0040","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1210\/jc.2006-1610","article-title":"Long-term treatment with recombinant insulin-like growth factor (IGF)-I in children with severe IGF-I deficiency due to growth hormone insensitivity","volume":"92","author":"Chernausek","year":"2007","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"2","key":"10.1016\/j.ghir.2020.01.001_bb0045","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1210\/jc.2012-3704","article-title":"Recommended IGF-I dosage causes greater fat accumulation and osseous maturation than lower dosage and may compromise long-term growth effects","volume":"98","author":"Guevara-Aguirre","year":"2013","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"5","key":"10.1016\/j.ghir.2020.01.001_bb0050","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1159\/000371798","article-title":"Houchard a; EU IGFD registry study group. Effectiveness and safety of rhIGF-1 therapy in children: the European Increlex\u00ae growth forum database experience","volume":"83","author":"Bang","year":"2015","journal-title":"Horm Res Paediatr."},{"issue":"4","key":"10.1016\/j.ghir.2020.01.001_bb0055","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1210\/er.2010-0023","article-title":"Evidence for a continuum of genetic, phenotypic, and biochemical abnormalities in children with growth hormone insensitivity","volume":"32","author":"David","year":"2011","journal-title":"Endocr. Rev."},{"issue":"2","key":"10.1016\/j.ghir.2020.01.001_bb0060","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1210\/er.2018-00146","article-title":"Nonclassical GH insensitivity: characterization of mild abnormalities of GH action","volume":"40","author":"Storr","year":"2019","journal-title":"Endocr. Rev."},{"issue":"4","key":"10.1016\/j.ghir.2020.01.001_bb0065","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1210\/js.2016-1119","article-title":"Novel dominant-negative GH receptor mutations expands the Spectrum of GHI and IGF-I deficiency","volume":"1","author":"Vairamani","year":"2017","journal-title":"J Endocr Soc."},{"issue":"5","key":"10.1016\/j.ghir.2020.01.001_bb0070","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1530\/EJE-18-0042","article-title":"Phenotypic spectrum and responses to recombinant human IGF1 (rhIGF1) therapy in patients with homozygous intronic pseudoexon growth hormone receptor mutation","volume":"178","author":"Chatterjee","year":"2018","journal-title":"Eur. J. Endocrinol."},{"issue":"1","key":"10.1016\/j.ghir.2020.01.001_bb0075","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1038\/s41467-018-04521-0","article-title":"Dominant-negative STAT5B mutations cause growth hormone insensitivity with short stature and mild immune dysregulation","volume":"9","author":"Klammt","year":"2018","journal-title":"Nat. Commun."},{"issue":"4","key":"10.1016\/j.ghir.2020.01.001_bb0080","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1056\/NEJMoa1415227","article-title":"Paternally inherited IGF2 mutation and growth restriction","volume":"373","author":"Begemann","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.ghir.2020.01.001_bb0085","doi-asserted-by":"crossref","first-page":"E703","DOI":"10.1210\/jc.2013-3718","article-title":"IGFALS gene dosage effects on serum IGF-I and glucose metabolism, body composition, bone growth in length and width, and the pharmacokinetics of recombinant human IGF-I administration","volume":"99","author":"H\u00f6gler","year":"2014","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"6","key":"10.1016\/j.ghir.2020.01.001_bb0090","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1530\/EJE-16-0999","article-title":"Clinical and biochemical characteristics and bone mineral density of homozygous, compound heterozygous and heterozygous carriers of three novel IGFALS mutations","volume":"176","author":"I\u015f\u0131k","year":"2017","journal-title":"Eur. J. Endocrinol."},{"issue":"12","key":"10.1016\/j.ghir.2020.01.001_bb0095","doi-asserted-by":"crossref","first-page":"4568","DOI":"10.1210\/jc.2017-01411","article-title":"Pharmacokinetics of IGF-1 in PAPP-A2-deficient patients, growth response, and effects on glucose and bone density","volume":"102","author":"Cabrera-Salcedo","year":"2017","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"11","key":"10.1016\/j.ghir.2020.01.001_bb0100","doi-asserted-by":"crossref","first-page":"3879","DOI":"10.1210\/jc.2016-2751","article-title":"Treatment with recombinant human insulin-like growth Factor-1 improves growth in patients with PAPP-A2 deficiency","volume":"101","author":"Mu\u00f1oz-Calvo","year":"2016","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"24","key":"10.1016\/j.ghir.2020.01.001_bb0105","doi-asserted-by":"crossref","first-page":"21849","DOI":"10.1074\/jbc.M102191200","article-title":"Pregnancy-associated plasma protein-A2 (PAPP-A2), a novel insulin-like growth factor-binding protein-5 proteinase","volume":"276","author":"Overgaard","year":"2001","journal-title":"J. Biol. Chem."},{"issue":"4","key":"10.1016\/j.ghir.2020.01.001_bb0110","doi-asserted-by":"crossref","first-page":"363","DOI":"10.15252\/emmm.201506106","article-title":"Mutations in pregnancy-associated plasma protein A2 cause short stature due to low IGF-I availability","volume":"8","author":"Dauber","year":"2016","journal-title":"EMBO Mol Med."},{"issue":"7","key":"10.1016\/j.ghir.2020.01.001_bb0115","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1210\/js.2018-00106","article-title":"PAPPA2 as a therapeutic modulator of IGF-I bioavailability: in vivo and in vitro evidence","volume":"2","author":"Andrew","year":"2018","journal-title":"J Endocr Soc."},{"issue":"2","key":"10.1016\/j.ghir.2020.01.001_bb0120","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.ecl.2012.04.010","article-title":"The insulin-like growth factors and growth disorders of childhood","volume":"41","author":"Backeljauw","year":"2012","journal-title":"Endocrinol. Metab. Clin. N. Am."},{"key":"10.1016\/j.ghir.2020.01.001_bb0125","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.ghir.2017.12.009","article-title":"Treatment of growth failure in the absence of GH signaling: the Ecuadorian experience","volume":"38","author":"Guevara-Aguirre","year":"2018","journal-title":"Growth Hormon. IGF Res."}],"container-title":["Growth Hormone & IGF Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096637420300010?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096637420300010?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T22:51:38Z","timestamp":1761087098000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1096637420300010"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4]]},"references-count":25,"alternative-id":["S1096637420300010"],"URL":"https:\/\/doi.org\/10.1016\/j.ghir.2020.01.001","relation":{},"ISSN":["1096-6374"],"issn-type":[{"value":"1096-6374","type":"print"}],"subject":[],"published":{"date-parts":[[2020,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Therapy with recombinant human IGF-1 for children with primary insulin-like growth factor-I deficiency","name":"articletitle","label":"Article Title"},{"value":"Growth Hormone & IGF Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ghir.2020.01.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}